couter

IBEX Limited sells outsourced data processing and cloud-based business process automation services to enterprises across the globe. The next catalyst is Nov 17, 2026 — Insider Bruce Neil Dawson sells 4,050 shares, which will test the market’s reaction to insider selling amid a backdrop of rising macro volatility.

  • Revenue grew 15.4% YoY to $655.03M in 2026, with net income at $52.36M and free cash flow of $29.67M (TTM).
  • Debt-to-equity ratio of 0.01x suggests a highly leveraged capital structure, while net margin of 8.0% reflects disciplined cost management.
  • Share repurchase program announced in May 2026 signals confidence in intrinsic value, though the next catalyst will test whether the market sees this as a sign of strength or weakness.

The Read

IBEX's product launches historically trigger a median absolute stock move of about 18%.
Nov 17, 2026 — Insider Bruce Neil Dawson sells 4,050 shares
Chart by TradingView

The schedule

  • Tue17Nov

    The insider sale may test investor sentiment around the company's valuation and strategic direction, particularly in light of recent macroeconomic conditions and sector performance.

  • Mon23Nov

    The broader market decline may test the company's resilience against regional economic slowdowns and potential weakness in the Spanish market.

  • Thu10Dec

    The shareholder meeting may test the company's ability to communicate its strategic priorities and financial outlook, which could influence investor confidence and stock performance.

  • Fri15Jan

    The execution of the share repurchase program and capital allocation update may test the company's ability to manage its balance sheet and signal confidence in its future earnings potential.

  • Wed3Feb

    The earnings release will test whether the company can maintain its guidance reset and margin commentary, which historically have driven more price movement than the actual reported results.

  • Wed5May

    This release will test the company's ability to maintain its forward guidance and mix commentary, which historically have been more impactful than the actual results.

  • Wed4Aug

    The earnings release will test whether the company can maintain its guidance reset and margin commentary, which historically have driven more price movement than the actual reported results.

  • Wed3Nov

    This release will test the company's ability to maintain its forward guidance and mix commentary, which historically have been more impactful than the actual results.

Past

  • Thu5Nov

    Actual outcome: Bull · $56.05 at outcome

    IBEX reported earnings that significantly exceeded expectations, with revenue surpassing estimates by a notable margin. The strong results were driven by robust demand in key markets and improved operational efficiency, leading to a sharp upward move in the stock. The earnings call highlighted long-term growth opportunities and positive guidance for the next quarter. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +20.5% from 2026-10-29 to 2026-11-12 (~2.6σ vs typical 10d vol). Target evaluation date 2026-11-15 (not yet reached as of 2026-11-12). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-13: +24.7% from 2026-10-30 (~3.1σ). Target evaluation date 2026-11-15 (not yet reached as of 2026-11-13). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-16: +27.5% from 2026-11-02 (~3.4σ). Target date 2026-11-15 reached; move through 2026-11-16 observed.

    IBEX reported earnings that significantly exceeded expectations, with revenue surpassing estimates by a notable margin. The strong results were driven by robust demand in key markets and improved operational efficiency, leading to a sharp upward move in the stock. The earnings call highlighted long-term growth opportunities and positive guidance for the next quarter. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +20.5% from 2026-10-29 to 2026-11-12 (~2.6σ vs typical 10d vol). Target evaluation date 2026-11-15 (not yet reached as of 2026-11-12). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-13: +24.7% from 2026-10-30 (~3.1σ). Target evaluation date 2026-11-15 (not yet reached as of 2026-11-13). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-16: +27.5% from 2026-11-02 (~3.4σ). Target date 2026-11-15 reached; move through 2026-11-16 observed.

  • Fri18Sep

    Actual outcome: Bull · $42.63 at outcome

    The stock rallied following the Sierra AI Partnership update, with the closing price on the outcome date reaching $42.63, surpassing the bull target of $36.50. The positive price action was driven by strong monetization progress and improved client conversion metrics, signaling enhanced partnership value and long-term growth potential. The stock continued to rise, reflecting market confidence in the strategic direction and performance outcomes.

    Mid-quarter update on the monetization progress and client conversion metrics for the Sierra AI partnership.

  • Wed5Aug

    Actual outcome: Bull · $37.01 at outcome

    IBEX reported Fiscal Q4 2026 EPS of $0.99, exactly matching consensus estimates. The stock exceeded the bull target and held strong above $37, driven by favorable initial FY2027 revenue and margin guidance that reassured investors about the company's continued growth trajectory. This solid forward outlook allowed the stock to maintain its upward momentum despite the lack of a headline earnings beat.

    Fiscal Q4 2026 earnings report and the critical initial FY2027 revenue and margin guidance.

  • Wed5Aug

    Actual outcome: Bull · $35.13 at outcome

    IBEX reported Q2 EPS of $0.99, exactly meeting consensus estimates. The stock maintained its strong positioning and closed well above the $31.98 bull target, as the in-line earnings results and steady fundamental execution reassured investors and supported the elevated valuation.

    IBEX reported Q2 EPS of $0.99, exactly meeting consensus estimates. The stock maintained its strong positioning and closed well above the $31.98 bull target, as the in-line earnings results and steady fundamental execution reassured investors and supported the elevated valuation.

  • Wed15Jul

    Actual outcome: Bull · $35.07 at outcome

    Fears regarding the Trump administration's 'America First' scrutiny on offshore business process outsourcing (BPO) failed to materialize into actionable penalties or severe regulatory headwinds for the company. As the anticipated policy threats subsided without impacting IBEX's operational outlook or client demand, the stock rallied past the $34.50 bull target.

    Trump administration 'America First' policy updates and potential scrutiny of offshore business process outsourcing (BPO).

  • Thu25Jun

    Actual outcome: Bull · $30.37 at outcome

    IBEX shares rallied past the $31.80 bull target by early July as the company reinforced its AI capabilities to defend its competitive moat. The strategic appointment of a new Senior Vice President to lead the Wave iX AI-powered CX solutions suite signaled a strong commitment to expanding its automation offerings, reassuring investors amid the launch of competing agentic workflows by industry peers.

    Industry peers launch competing agentic workflows, testing IBEX's competitive moat at a $30.46 spot price.

  • Wed6May

    Actual outcome: Bull · $30.56 at outcome

    IBEX reported record Q3 revenue that grew 17% year-over-year and met EPS estimates, prompting the company to raise its full-year revenue and adjusted EBITDA guidance. The strong financial results, combined with a new strategic AI partnership with Sierra and the announcement of a $20 million share repurchase program, drove the stock's 8.7% rally.

    Quarterly earnings following the Q2 post-beat sell-off; focus on whether margin expansion offset AI-related volume compression.

  • Fri10Apr

    Actual outcome: Bull · $29.03 at outcome

    IBEX's stock rose as the market focused on the company's strong Q2 2026 financial results, including a 16.7% revenue increase and 35% growth in its high-margin HealthTech segment. Investors prioritized the successful strategic pivot toward AI-powered solutions and specialized sectors, which mitigated fears that 'America First' reshoring policies would significantly impair its offshore delivery model.

    Analysis of potential tariffs or tax penalties on offshore service providers impacting IBEX's delivery centers in the Philippines and Jamaica.

  • Sun15Mar

    Actual outcome: Bear · $26.79 at outcome

    The anticipated major contract win failed to materialize by the event date, leaving IBEX's high CapEx and negative free cash flow profile without the necessary fundamental validation for a re-rating. Instead, the stock was weighed down by news of institutional selling from American Century Companies, resulting in a stagnant price performance that remains significantly below the

    Focus on validating the high CapEx/negative Free Cash Flow profile. News of a significant, multi-year digital CX contract win would validate capacity investments and signal FCF turnaround potential, driving a re-rating towards DCF ($33.77). A loss of a major client due to AI/automation adoption would be catastrophic. The oversold RSI provides asymmetric upside potential if news is positive.

  • Thu5Feb

    Actual outcome: Bear · $29.80 at outcome

    IBEX reported an EPS beat ($0.87 vs $0.855), record quarterly revenue, and raised its fiscal year guidance, fundamentally aligning with the bull case. However, the stock plummeted 12.9% following the report, settling significantly below the bear floor ($30.10 vs $35.00). This severe negative price action indicates the market rejected the results, likely due to underlying concerns regarding the quality of earnings, disappointing sequential growth, or specific margin pressures that overwhelmed the positive headline figures and guidance raise.

    Release of second fiscal quarter results. Investors will focus on continued margin expansion and sequential revenue growth to confirm the low P/E multiple is unwarranted.